Table 2.
Persistent symptoms and sequelae investigated among patients with COVID-19, discharged alive and who agreed to follow up interview (n = 456).
| General health status after COVID-19, N (%) | Value |
|---|---|
| <5 | 11 (2.42%) |
| 5–6 | 65 (14.32%) |
| 7–8 | 234 (51.54%) |
| 9–10 | 144 (31.72%) |
| Severe medical issues after COVID-19, N (%) | 88 (19.38%) |
| ER admission | 47 (10.35%) |
| Hospitalization | 30 (6.61%) |
| - Respiratory problems | 5 (1.10%) |
| - Neurologic problems | 1 (0.22%) |
| - Psychiatric problem | 0 |
| - GI problems | 1 (0.22%) |
| - Hepatologic problems | 2 (0.44%) |
| - Cardiovascular problems | 17 (3.72%) |
| - Other | 15 (3.30%) |
| Other | 15 (3.30%) |
| Respiratory symptoms, N (%) | |
| Dyspnea at rest (≥5) | 57 (12.5%) |
| Exertional dyspnea | |
| - mMRC 0 | 128 (28.32%) |
| - mMRC ≥ 1 | 324 (71.68%) |
| Cough | 73 (16.08%) |
| GI symptoms, N (%) | |
| Altered gastrointestinal function (altered bowel habits and bloating) | 149 (32.75%) |
| Other symptoms, N (%) | |
| Smell disorder (<5) | 18 (3.96%) |
| Taste disorder (<5) | 13 (2.86%) |
| Memory disorder (<5) | 15 (3.47%) |
| Fatigue | 230 (54.63%) |
| Headache | 73 (17.38%) |
| Sleep difficulties | 147 (32.38%) |
| Decreased appetite | 34 (7.49%) |
| Limitations to daily activities (limitations to daily activities + troubled walking) | 69 (16.35%) |
| Anxiety (≥5) | 104 (23.16%) |
| Myalgia | 94 (22.27%) |